Using Multidisciplinary Care to Optimize Outcomes in GVHD
Sharing closing thoughts on acute and chronic GVHD management, expert panelists first consider the value of multidisciplinary care.
Treatment Advances on the Horizon for Acute GVHD
Shifting their focus to acute graft versus host disease, panelists reflect on evolving treatment strategies and novel therapeutics.
Treatment Advances on the Horizon for Chronic GVHD
Expert panelists share their perspectives on ongoing treatment evolutions in the setting of chronic graft versus host disease.
Steroid-Refractory Chronic GVHD: Selecting and Sequencing Therapy
Following their review of available treatment for steroid refractory chronic GVHD, experts consider how they would optimally select and sequence therapy.
Treatment Armamentarium for Steroid-Refractory Chronic GVHD
Comprehensive discussion on each of the 3 standard-of-care treatment options for patients with steroid refractory chronic GVHD.
Frontline Treatment Strategies for Chronic GVHD
An overview of the frontline treatment armamentarium for patients diagnosed with chronic graft versus host disease.
Improving the Early Identification of Chronic Graft Versus Host Disease
Shifting their focus to chronic graft versus host disease, panelists emphasize the importance of early identification and diagnosis.
Identifying the Role of the Microbiome in HSCT and GVHD
Expert panelists review the role of the microbiome in the context of hematopoietic stem cell transplantation and steroid-refractory acute GVHD.
Steroid-Refractory GVHD: Enrolling Patients on Clinical Trials
Key opinion leaders highlight the value of clinical trials and share their perspective on enrolling patients in the setting of acute GVHD.
Overview of Therapy for Steroid-Refractory Acute Graft Versus Host Disease
Comprehensive discussion on the treatment options available for patients diagnosed with steroid-refractory acute GVHD.
What is the Role of Biomarker Testing in GVHD?
A brief review of the evolving utilization of biomarker testing in acute graft versus host disease, particularly for prognostic evaluation.
Challenges in Making a Diagnosis of Acute GVHD
Focusing on acute graft versus host disease, panelists consider tools and methods that help to overcome challenges in making a differential diagnosis.
Educating Patients and Caregivers on the Impact of Graft Versus Host Disease
Expert perspectives on how best to educate patients and caregivers on graft versus host disease symptoms and quality of life.
Graft Versus Host Disease: Optimizing Prophylaxis Techniques
Shared insight on standard-of-care prophylactic methods employed in the management of patients with graft versus host disease.
Understanding Pathophysiology and Risk of Graft Versus Host Disease
Expert panelists spearhead a discussion on the pathophysiology driving both acute and chronic graft versus host disease.
HSCT Approaches to Retain GVL While Preventing GVHD
Expert perspectives on novel transplantation strategies to prevent or improve outcomes in graft-versus-host disease.
Novel Targeted Agents in GVHD: The FLIGHT and AGAVE-201 Trials
Brief insight on the FLIGHT and AGAVE-201 trials in chronic GVHD, which analyzed itacitinib, a JAK inhibitor, and axatilimab, a CSF1R inhibitor, respectively.
Chronic GVHD: Novel Treatment Approaches With Approved Agents
Considerations for novel treatment approaches with approved agents in combination or the frontline setting of chronic graft-vs-host disease.
Selecting Second-Line Therapy for Chronic GVHD
Shared insight on how best to select ibrutinib, belumosudil, or ruxolitinib for patients with steroid-refractory chronic graft-vs-host disease.
Chronic GVHD: Real-World Use of Ruxolitinib
Closing out his summation of ruxolitinib in chronic GVHD, Yi-Bin Chen, MD, considers how real-world use compares with the REACH3 trial results.
Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma
Dr. Halmos on Trastuzumab Deruxtecan in NSCLC
Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations
Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.